Publications by authors named "Colin Coon"

Claim this Profile
G
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.
Sheeba Jacob, Tia H Turner, Jinyang Cai, Konstantinos V Floros, Ann K Yu, Colin M Coon

PNAS Nexus· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
Richard Kurupi, Konstantinos V Floros, Sheeba Jacob, Ayesha T Chawla, Jinyang Cai, Colin M Coon

Cancer Res Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M Dalton, Colin Coon

Cell Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-based Rational Combinations are Effective in Models of -amplified Neuroblastoma.
Krista M Dalton, Kateryna Krytska, Timothy L Lochmann, Renata Sano, Colleen Casey, Colin Coon

Mol Cancer Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA.
Carter K Fairchild, Konstantinos V Floros, Sheeba Jacob, Colin M Coon, Madhavi Puchalapalli

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis.
Konstantinos V Floros, JinYang Cai, Sheeba Jacob, Richard Kurupi, Carter K Fairchild, Colin M Coon

Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Ewing Family of Tumors Relies on BCL-2 and BCL-X to Escape PARP Inhibitor Toxicity.
Daniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, Colin M Coon, Krista M Powell

Clin Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target.
Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L Lochmann, Colin M Coon

Clin Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis